SCHEMBL4183176

SCHEMBL4183176

Nc1ccccc1NC(=O)c1ccc2c(c1)CCC2NC(=O)COc1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 18/20 0.46
HDAC2 Q92769 9/20 0.46
HDAC3 O15379 8/20 0.46
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
ABL1 P00519 2/20 0.43
PDGFRB P09619 2/20 0.43
KDR P35968 2/20 0.43
HDAC11 Q96DB2 5/20 0.42
HDAC8 Q9BY41 5/20 0.42
HDAC6 Q9UBN7 5/20 0.42
HDAC4 P56524 4/20 0.42
HDAC7 Q8WUI4 4/20 0.42
HDAC10 Q969S8 4/20 0.42
HDAC9 Q9UKV0 4/20 0.42
HDAC5 Q9UQL6 4/20 0.42
CYP3A4 P08684 2/20 0.42
NCOR2 Q9Y618 2/20 0.42
NCOR1 O75376 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4185657 0.91 KMT2A (0.45) KMT2AMEN1POLBKDRNAMPT
SCHEMBL13653164 0.86 KMT2A (0.41) KMT2AMEN1POLBABL1PDGFRB
SCHEMBL4190946 0.84 HDAC1 (0.50) HDAC1HDAC2HDAC3HDAC11HDAC8
SCHEMBL13653113 0.83 HDAC1 (0.60) HDAC1HDAC2HDAC3HDAC11HDAC8
SCHEMBL4187020 0.81 HDAC1 (0.61) HDAC1HDAC2HDAC3KMT2APOLB
SCHEMBL13653134 0.79 HDAC1 (0.48) HDAC1HDAC2HDAC3KMT2AMEN1
SCHEMBL4198505 0.79 HDAC1 (0.54) HDAC1HDAC2HDAC3HDAC11HDAC8
SCHEMBL4197796 0.78 HDAC3 (0.50) HDAC1HDAC2HDAC3HDAC11HDAC8
SCHEMBL4190658 0.78 HDAC1 (0.50) HDAC1HDAC2HDAC3HDAC11HDAC8
SCHEMBL4191098 0.78 HDAC1 (0.50) HDAC1HDAC2HDAC3HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247590-A1 Indane amides BAYER PHARMACEUTICLAS CORPORATION (US) 2009-10-01 US disclosed
US-20090247590-A1 Indane amides BAYER PHARMACEUTICLAS CORPORATION (US) 2009-10-01 US disclosed
US-20090247590-A1 Indane amides BAYER PHARMACEUTICLAS CORPORATION (US) 2009-10-01 US disclosed
EP-1802577-A1 INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY Bayer Pharmaceuticals Corporation (US) 2007-07-04 EP disclosed
WO-2006062580-A1 INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247590-A1 Indane amides MKI67, PPIP5K2, CCNA1 HDAC1 579/4885HDAC2 641/4885HDAC3 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.